Evaluation of the Relationship Between Prostate-Specific Antigen and Prostate Size and Also PSA and BMI in Subjects Referred to the Check-up Clinic of Razavi Hospital


Department of Education and Research, Razavi Hospital, Mashhad, IR Iran



Background: Defining the optimal prostate-specific antigen threshold to identify the patients at the highest risk of prostate cancer has always been a controversial issue. Objectives: This study aims to analyze the diagnostic value of PSA and also evaluate the relationship between PSA (prostate-specific antigen) and BMI (body mass index) as well as PSA and prostate size and volume in asymptomatic subjects referred to the Check-up Clinic of Razavi Hospital. Patients and Methods: In this descriptive, cross-sectional and retrospective study; the demographic data as well as total PSA and also prostate size of 1149 subjects who had referred to the Check-up Clinic of Razavi Hospital from 2006 to 2011 were evaluated according to their sonography reports. All the subjects were asymptomatic. Data were analyzed using SPSS as well as descriptive and statistical tests. Results: The mean age of the subjects was 45 ± 12 and BMI was reported 27 ± 8. Very low and inverse correlation was determined between PSA and BMI. Non-significant correlation was reported (P = 0.08, r = 0.054). It was also observed that the correlation between PSA and prostate volume was greater than the correlation between PSA and height, width and length of prostate separately (P = 0.001, r = 0.394). Conclusions: According to this study, there is a direct relationship between the age and PSA level. The more the age increases, the more PSA level increases. The highest average of PSA level is reported at the age of 60-69, so it can be considered as an appropriate suggestion for the screening of prostate cancer at least in North East of Iran. Although non-significant relationship is observed between PSA level and BMI in this study; but a significant relation has been reported in other studies focusing on the symptomatic subjects up to now. The mentioned significant relation may be the result of PSA > 10. The relation between these factors may become more obvious if a high amount of PSA is reported. This may lead us to develop other studies including the comparison between the mentioned factors on symptomatic and nonsymptomatic subjects.


1. Carter HB, partin AW. Diagnosis and staging of prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA editors. Campbell-Walsh Urology. 8th ed. Sydney: Elsevier Health Sciences; 2002. 
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30. 
3. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17(4):337–47. 
4. Glovamucci EP. Nutritional and environmental epidemiology of prostate cancer. In: Carrol P, amico AV editors. prostate cancer principles and practice. 15th ed. Philadelphia: wolters kluwer company; 2002. 
5. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, et al. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. World J Urol. 2007;25(1):95–103. 
6. Olsen SH, Walzak J. Prostate cancer: rate and risk. Atlantic cancer genetics network. 2002;68(4):36–8. 
7. Tulloch-Reid MK, Aiken WD, Morrison BF, Tulloch T, Mayhew R, Wan RL, et al. Body mass index and prostate specific antigen levels in Jamaican men. West Indian Med J. 2011;60(3):316–21. 
8. Cox AK, Holliday RE, Gregory PS, Joseph WA, Fei D. The effects of body mass index on pretreatment characteristics, treatment choice, and response to treatment of intermediate- and highgrade prostate cancer. J Clin Oncol. 2012;30(5). 
9. Lujan M, Paez A, Llanes L, Miravalles E, Berenguer A. Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis. 2001;4(3):146–9. 
10. Ayatollahi SM, Khezri AA, Shirazi M, Lotfi M, Askarian M, Ariafar A, et al. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol. 2009;6(1):40–8. 
11. Pater LE, Hart KW, Blonigen BJ, Lindsell CJ, Barrett WL. Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population. Am J Clin Oncol. 2012;35(5):490–2